Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli

Biochemical and Biophysical Research Communications

Volumn 412, Issue 2, 2011, Pages 334-340

  Cheng, Yi Lin ^a   Huang, Wei Ching ^a   Chen, Chia Ling ^a   Tsai, Cheng Chieh ^a   Wang, Chi Yun ^a   Chiu, Wei Hsin ^a   Chen, Yuh Ling ^a   Lin, Yee Shin ^a   Chang, Chuan Fa ^a   Lin, Chiou Feng ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b Faculty of Medicine   (Taiwan)

Author keywords

Apoptosis; Bcl 2; Galectin 3; GSK 3 ; Leukemia

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CERAMIDE; CISPLATIN; GALECTIN 3; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; DRUG RESISTANCE, NEOPLASM; GALECTIN 3; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOCHONDRIA; MORPHOLINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; THIADIAZOLES; TRANSCRIPTION, GENETIC;

EID: 80052028371     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.07.099     Document Type: Article

References (45)

1. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
2. Califice S., Castronovo V., Bracke M., et al. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004, 23:7527-7536.
3. Nakahara S., Oka N., Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10:267-275.
4. Akahani S., Nangia-Makker P., Inohara H., et al. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997, 57:5272-5276.
5. Fukumori T., Kanayama H.O., Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist. Updat. 2007, 10:101-108.
6. Yang R.Y., Hsu D.K., Liu F.T. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93:6737-6742.
7. Song S., Mazurek N., Liu C., et al. Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res. 2009, 69:1343-1349.
8. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
9. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol. Cancer 2010, 9:144.
10. Maurer U., Charvet C., Wagman A.S., et al. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
11. Bhat R.V., Leonov S., Luthman J., et al. Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death. J. Alzheimers Dis. 2002, 4:291-301.
12. Bijur G.N., De Sarno P., Jope R.S. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J. Biol. Chem. 2000, 275:7583-7590.
13. Hetman M., Cavanaugh J.E., Kimelman D., et al. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 2000, 20:2567-2574.
14. Hongisto V., Smeds N., Brecht S., et al. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol. Cell. Biol. 2003, 23:6027-6036.
15. King T.D., Bijur G.N., Jope R.S. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 2001, 919:106-114.
16. Loberg R.D., Vesely E., Brosius F.C. Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J. Biol. Chem. 2002, 277:41667-41673.
17. Somervaille T.C., Linch D.C., Khwaja A. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood 2001, 98:1374-1381.
18. Song L., De Sarno P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 2002, 277:44701-44708.
19. Lin C.F., Chen C.L., Chiang C.W., et al. GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J. Cell Sci. 2007, 120:2935-2943.
20. Ougolkov A.V., Bone N.D., Fernandez-Zapico M.E., et al. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood 2007, 110:735-742.
21. Wang Z., Smith K.S., Murphy M., et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
22. Holmes T., O'Brien T.A., Knight R., et al. The role of glycogen synthase kinase-3beta in normal haematopoiesis, angiogenesis and leukaemia. Curr. Med. Chem. 2008, 15:1493-1499.
23. Patel S., Woodgett J. Glycogen synthase kinase-3 and cancer: good cop, bad cop?. Cancer Cell 2008, 14:351-353.
24. Asakuma J., Sumitomo M., Asano T., et al. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res. 2003, 63:1365-1370.
25. Lacour S., Hammann A., Grazide S., et al. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res. 2004, 64:3593-3598.
26. Lin C.F., Chen C.L., Lin Y.S. Ceramide in apoptotic signaling and anticancer therapy. Curr. Med. Chem. 2006, 13:1609-1616.
27. Noda S., Yoshimura S., Sawada M., et al. Role of ceramide during cisplatin-induced apoptosis in C6 glioma cells. J. Neurooncol. 2001, 52:11-21.
28. Stordal B., Davey M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59:696-699.
29. Schoepfer R. The pRSET family of T7 promoter expression vectors for Escherichia coli. Gene 1993, 124:83-85.
30. Ochieng J., Furtak V., Lukyanov P. Extracellular functions of galectin-3. Glycoconj. J. 2004, 19:527-535.
31. Fukumori T., Oka N., Takenaka Y., et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 2006, 66:3114-3119.
32. Yu F., Finley R.L., Raz A., et al. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J. Biol. Chem. 2002, 277:15819-15827.
33. Yin X.M., Oltvai Z.N., Korsmeyer S.J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369:321-323.
34. Maccarrone M., Nieuwenhuizen W.E., Dullens H.F., et al. Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin. Eur. J. Biochem. 1996, 241:297-302.
35. Maguer-Satta V., Burl S., Liu L., et al. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene 1998, 16:237-248.
36. Previati M., Lanzoni I., Corbacella E., et al. Cisplatin-induced apoptosis in human promyelocytic leukemia cells. Int. J. Mol. Med. 2006, 18:511-516.
37. Xu Q., Simpson S.E., Scialla T.J., et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
38. Dumic J., Dabelic S., Flogel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635.
39. Hoyer K.K., Pang M., Gui D. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol. 2004, 164:893-902.
40. Kim K., Mayer E.P., Nachtigal M. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim. Biophys. Acta 2003, 1641:13-23.
41. Lee Y.J., Song Y.K., Song J.J., et al. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp. Cell Res. 2003, 288:21-34.
42. Demetriou M., Granovsky M., Quaggin S., et al. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001, 409:733-739.
43. Fukumori T., Takenaka Y., Yoshii T., et al. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res. 2003, 63:8302-8311.
44. Dumic J., Lauc G., Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell. Physiol. Biochem. 2000, 10:149-158.
45. Zeng Y., Danielson K.G., Albert T.J., et al. HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. J. Bone Miner. Res. 2007, 22:1851-1861.